Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Carcinoma in Situ 1

Interventions

Gemcitabine 29pembrolizumab 20Cisplatin 20Magnetic Resonance Spectroscopy 17Specimen Handling 16Mitomycin 10enfortumab vedotin 9durvalumab 9Cystoscopy 9avelumab 8Nivolumab 8Fluorouracil 8Carboplatin 8Radiation 7Cystectomy 6atezolizumab 5Transurethral Resection of Bladder 5Radiotherapy 5Mitozytrex 5Docetaxel 5Biopsy 5tremelimumab 4sacituzumab govitecan 4erdafitinib 4dehydroftorafur 4Platinum 4Immunoglobulin G 4Disulfides 41,2-diaminocyclohexaneplatinum II citrate 4disitamab vedotin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Clinical Trials, Phase II as Topic × 90 days × Clear all
NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

enGene, Inc.

Phase 1/2 Recruiting
350 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡